uniQure N.V., a biopharmaceutical company, develops adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency. It also develops AMT-060, a gene therapy that is in Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical therapeutic for congestive heart failure; AMT-021, a gene therapy, which has completed Phase I clinical trial for acute intermittent porphyria; AMT-110, a gene therapy that is in Phase I/II clinical trial for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, University of California San Francisco, Bristol-Myers Squibb, and 4D Molecular Therapeutics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
April 9, 2018
RegMed Investors’ (RMi) closing bell; enjoying the high
April 5, 2018
RegMed Investors’ (RMi) closing bell; swimming with piranhas
April 5, 2018
RegMed Investors’ (RMi) pre-open: the drift of the oversold to a steep upside
April 3, 2018
RegMed Investors’ (RMi) closing bell; sector flip-flops through-out the session
April 2, 2018
RegMed Investors’ (RMi) closing bell; sector is technically broken
March 29, 2018
RegMed Investors’ (RMi) closing bell; an overdue rally
March 28, 2018
RegMed Investors’ (RMi) closing bell; the sector sputters and fails to rebound as …
March 27, 2018
RegMed Investors’ (RMi) closing bell; hammered and an all but a clean sweep of the sector
March 26, 2018
RegMed Investors’ (RMi) closing bell; the sector rallied at open, petered away and came back
March 26, 2018
RegMed Investors’ (RMi) pre-open: risk versus the “tools” of the market
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.